About Us About Us

Management Team

The drug development process is complex. Our management team offers deep expertise in all aspects of the process to drive products toward commercialization.


m_baker

Mark R. Baker

Chief Executive Officer

Mr. Baker joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President – Corporate, in 2009 became President, and has been CEO since March 2011. From 2003 to 2005, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City. From 1997 to 2001, he was Executive Vice President, Chief Legal Officer and Secretary of Continental Grain Company, a privately-held international agri-business and financial concern. Prior thereto, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm Dewey Ballantine. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.


v_wong

Pat Fabbio

Senior Vice President and Chief Financial Officer

Pat Fabbio joined the Company in November 2015 as Senior Vice President and Chief Financial Officer. Prior to joining Progenics, Pat was CFO of electroCore and VP Finance for NPS Pharmaceuticals, Inc., a publicly-traded, global rare disease company. Pat has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies including; VP Finance, Catalent Pharma Solutions, CFO of Ikano Therapeutics, and senior corporate finance, commercial and transactional roles at Sanofi as well as Corporate Controller for Biomatrix Inc. a publicly-traded biotechnology company that was acquired by Genzyme. Pat graduated from Pace University with a BBA in Accounting and from the Stern School of Business at New York University, with a Master’s Degree in Finance. He has received his certified public accountant license in New Jersey.


v_wong

Sheldon Hirt

Executive Vice President and General Counsel

Sheldon Hirt joined the Company in July, 2015 as Executive Vice President and General Counsel. Prior to joining Progenics Mr. Hirt was Senior Vice President, Legal Affairs and Assistant General Counsel at Actavis plc (now Allergan plc), where he worked from 2009 through July 2015 in positions of increasing responsibility in the legal department. From 2006 to 2009, Mr. Hirt served as Vice President and Chief Corporate Counsel at Barr Pharmaceuticals, Inc. From 2001 to 2006, he was Senior Counsel in the Johnson & Johnson Corporate legal group. Mr. Hirt began practicing law as a corporate associate at the law firm of Davis Polk & Wardwell in the firm’s New York and Frankfurt, Germany offices. He has an A.B. degree from Columbia College, an M.A. from the Columbia School of International and Public Affairs and a J.D. from the Columbia University School of Law. Prior to his graduate studies, Mr. Hirt served as an infantry officer in the U.S. Marine Corps, including in Operation Desert Shield, ground combat operations in Operation Desert Storm, and Operation Sharp Edge, the evacuation of non-combatant personnel from Liberia.


v_wong

Vivien Wong Ph.D.

Executive Vice President, Development

Dr. Wong has been Executive Vice President of Development since 2015. Prior to that date, she served as Senior Vice President of Operations and Portfolio Management and Vice President of Product Development. For three years before joining Progenics in 2007, Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004, she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a Ph.D. in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.


Jeff Summer

Jeff Summer

Senior Vice President, Strategy and Performance

As Senior Vice President, Strategy and Performance Jeff facilitates company effectiveness through strategy implementation, organization design and talent development. Prior to joining Progenics, Jeff’s key experience includes nearly fourteen years as a Partner at Deloitte and later working as an independent consultant. While at Deloitte, in addition to leading the firm’s global talent management practice, Jeff served a two-year secondment as the U.S. Firm’s CHRO. Jeff has worked with numerous companies in Healthcare including Pfizer, Financial Services including Goldman Sachs and Professional Services Baker & McKenzie. Jeff’s pro-bono work with global not-for-profit organizations that serve children has most recently included projects in India, Kenya, Senegal and the United States.


Meryl J. Longval

Meryl J. Longval

Head of Corporate Operations

Ms. Longval joined Progenics in 2002 and is the Head of Corporate Operations. She has held increasing levels of responsibility since joining Progenics. She has over 30-years’ experience in facility and materials management functions. Prior to joining Progenics, Ms. Longval was Director of Logistics at Ortec International; Director of Worldwide Planning and Product Distribution at Roche Molecular Systems; and Director of Materials Management at Genzyme. Ms. Longval holds a B.S. in Accounting from the University of Massachusetts and an M.S. in Management from Lesley College.